These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 15631542)
1. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Bielory L; Lien KW; Bigelsen S Drugs; 2005; 65(2):215-28. PubMed ID: 15631542 [TBL] [Abstract][Full Text] [Related]
2. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Castillo M; Scott NW; Mustafa MZ; Mustafa MS; Azuara-Blanco A Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD009566. PubMed ID: 26028608 [TBL] [Abstract][Full Text] [Related]
3. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends. Ben-Eli H; Solomon A Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):411-416. PubMed ID: 30020258 [TBL] [Abstract][Full Text] [Related]
5. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S; McTavish D Drugs; 1995 Dec; 50(6):1032-49. PubMed ID: 8612470 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic options in ocular allergic disease. Hingorani M; Lightman S Drugs; 1995 Aug; 50(2):208-21. PubMed ID: 8521755 [TBL] [Abstract][Full Text] [Related]
7. Drugs for allergic rhinitis and allergic conjunctivitis. Med Lett Drugs Ther; 2021 Apr; 63(1622):57-64. PubMed ID: 33848281 [No Abstract] [Full Text] [Related]
8. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Owen CG; Shah A; Henshaw K; Smeeth L; Sheikh A Br J Gen Pract; 2004 Jun; 54(503):451-6. PubMed ID: 15186569 [TBL] [Abstract][Full Text] [Related]
9. Optimal use of topical agents for allergic conjunctivitis. Mösges R; Hassan HA; Wenzel MR BioDrugs; 1997 Oct; 8(4):250-64. PubMed ID: 18020517 [TBL] [Abstract][Full Text] [Related]
10. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Abelson MB; Lanier RQ Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434 [TBL] [Abstract][Full Text] [Related]
11. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Crampton HJ Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545 [TBL] [Abstract][Full Text] [Related]
12. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Spangler DL; Abelson MB; Ober A; Gotnes PJ Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132 [TBL] [Abstract][Full Text] [Related]
13. Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. Figus M; Fogagnolo P; Lazzeri S; Capizzi F; Romagnoli M; Canovetti A; Iester M; Ferreras A; Rossetti L; Nardi M Eur J Ophthalmol; 2010; 20(5):811-8. PubMed ID: 20383847 [TBL] [Abstract][Full Text] [Related]
14. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Dechant KL; Goa KL Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Avunduk AM; Tekelioglu Y; Turk A; Akyol N Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412 [TBL] [Abstract][Full Text] [Related]
17. [Seasonal and Perennial Allergic Rhinoconjunctivitis]. Schröder K; Finis D; Meller S; Buhren BA; Wagenmann M; Geerling G Laryngorhinootologie; 2017 Feb; 96(2):89-97. PubMed ID: 28291999 [TBL] [Abstract][Full Text] [Related]
18. Interactions of olopatadine and selected antihistamines with model and natural membranes. Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332 [TBL] [Abstract][Full Text] [Related]
20. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Ousler GW; Workman DA; Torkildsen GL Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]